Iberdomide
- Generic Name
- Iberdomide
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C25H27N3O5
- CAS Number
- 1323403-33-3
- Unique Ingredient Identifier
- 8V66F27X44
- Background
Iberdomide (CC-220) has been used in trials studying the treatment of Systemic Lupus Erythematosus.
- Associated Conditions
- -
- Associated Therapies
- -
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Carl Ola Landgren, MD, PhD
- Target Recruit Count
- 30
- Registration Number
- NCT05896228
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
- First Posted Date
- 2023-04-24
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1216
- Registration Number
- NCT05827016
- Locations
- 🇫🇷
CHU Hôpital Sud, Amiens Cedex 1, France
🇨🇳Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
🇨🇳The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-10-18
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 200
- Registration Number
- NCT05583617
- Locations
- 🇫🇷
IGR, Villejuif, France
🇦🇺Prince of Wales Hospital; Haematology, Randwick, New South Wales, Australia
🇦🇺St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia
A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-09-29
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 7
- Registration Number
- NCT05560399
- Locations
- 🇺🇸
Icahn School of Medicine, New York, New York, United States
NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide
- Conditions
- Interventions
- First Posted Date
- 2022-09-28
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 480
- Registration Number
- NCT05558319
- Locations
- 🇪🇸
Hospital Principe de Asturias, Alcalá de Henares, Madrid, Spain
🇪🇸Hospital Germans Trias i Pujol (ICO BADALONA), Badalona, Spain
🇪🇸Clinica Universidad Navarra (CUN), Pamplona, Navarra, Spain
Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.
- Conditions
- Interventions
- First Posted Date
- 2022-09-02
- Last Posted Date
- 2022-09-02
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 140
- Registration Number
- NCT05527340
- Locations
- 🇪🇸
Hospital Universitario de Canarias, La Laguna, Spain
🇪🇸Hospital Universitario 12 de Octubre, Madrid, Spain
🇪🇸ClÃnica Universidad de Navarra, Pamplona, Spain
COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide
- Conditions
- Interventions
- First Posted Date
- 2022-06-28
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 80
- Registration Number
- NCT05434689
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸University of Wisconsin, Madison, Wisconsin, United States
🇺🇸Oregon Health and Science University, Portland, Oregon, United States
Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study
- Conditions
- Interventions
- First Posted Date
- 2022-05-26
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 18
- Registration Number
- NCT05392946
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT)
- First Posted Date
- 2022-04-29
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 86
- Registration Number
- NCT05354557
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge (Consent and Followup), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Consent and Follow-Up only), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (Consent and Follow up), Montvale, New Jersey, United States
Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-03-21
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- iTeos Belgium SA
- Target Recruit Count
- 16
- Registration Number
- NCT05289492
- Locations
- 🇺🇸
Fred Hutchinson Cancer Center, Seattle, Washington, United States
🇺🇸Eastern Connecticut Hematology & Oncology, Norwich, Connecticut, United States
🇧🇪ZNA Cadix, Antwerp, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.